Nicholas Girard, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer, highlighting data from the phase 3 TROPION-Lung01 study.
Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.